Biotech Values

[DewDiligence]

OCRX expects phase-2b futility/enrollment-size feedback from DSMB in about four weeks. Patient recruitment in the phase-2b trial has gone more slowly than expected, and hence full enrollment is now anticipated by the end of 2015, a delay from the prior guidance of 1H15.

New disclosure: The phase-2b futility/enrollment-size analysis uses 0.01 of alpha spend.

(Source: today’s Cowen webcast.)